AMPK activation has been strongly associated with cardioprotection during pathological cardiac events, particularly in ischemia-reperfusion injury, heart failure, and metabolic diseases like diabetic cardiomyopathy. This evidence concerns the gene PRKAA2 and metabolic disease.